Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29


irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.

Pignon JC, Jegede O, Shukla SA, Braun DA, Horak CE, Wind-Rotolo M, Ishii Y, Catalano PJ, Grosha J, Flaifel A, Novak JS, Mahoney KM, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Choueiri TK, Wu CJ, Atkins MB, McDermott DF, Signoretti S.

Clin Cancer Res. 2019 Apr 1;25(7):2174-2184. doi: 10.1158/1078-0432.CCR-18-3206. Epub 2019 Jan 22.


Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA.

Cell. 2017 Nov 2;171(4):934-949.e16. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.


Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, Melero I, Ascierto PA.

Drugs. 2016 Jun;76(9):925-45. doi: 10.1007/s40265-016-0588-x. Review.


Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.

Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ, Horak CE, Inzunza HD, Yu B, Martinez AJ, Younos I, Weber JS.

Clin Cancer Res. 2015 Feb 15;21(4):712-20. doi: 10.1158/1078-0432.CCR-14-2468. Epub 2014 Dec 18.


Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA.

J Clin Oncol. 2013 Dec 1;31(34):4311-8. doi: 10.1200/JCO.2013.51.4802. Epub 2013 Oct 21.


Nivolumab plus ipilimumab in advanced melanoma.

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M.

N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.


Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer.

Horak CE, Pusztai L, Xing G, Trifan OC, Saura C, Tseng LM, Chan S, Welcher R, Liu D.

Clin Cancer Res. 2013 Mar 15;19(6):1587-95. doi: 10.1158/1078-0432.CCR-12-1359. Epub 2013 Jan 22.


Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.

Harbison CT, Horak CE, Ledeine JM, Mukhopadhyay P, Malone DP, O'Callaghan C, Jonker DJ, Karapetis CS, Khambata-Ford S, Gustafson N, Trifan OC, Chang SC, Ravetto P, Iv GA.

Arch Pathol Lab Med. 2013 Jun;137(6):820-7. doi: 10.5858/arpa.2012-0367-OA. Epub 2012 Oct 3.


Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer.

Marshall JC, Collins JW, Nakayama J, Horak CE, Liewehr DJ, Steinberg SM, Albaugh M, Vidal-Vanaclocha F, Palmieri D, Barbier M, Murone M, Steeg PS.

J Natl Cancer Inst. 2012 Sep 5;104(17):1306-19. doi: 10.1093/jnci/djs319. Epub 2012 Aug 21.


The cetuximab experience: developing predictive biomarkers in oncology.

Harbison CT, Horak CE, Khambata-Ford S.

Per Med. 2011 Mar;8(2):149-159. doi: 10.2217/pme.10.78.


Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR.

J Clin Oncol. 2010 Feb 20;28(6):918-27. doi: 10.1200/JCO.2009.25.2890. Epub 2010 Jan 25.


Altered gene and protein expression by Nm23-H1 in metastasis suppression.

Lee JH, Marshall JC, Steeg PS, Horak CE.

Mol Cell Biochem. 2009 Sep;329(1-2):141-8. doi: 10.1007/s11010-009-0124-3. Epub 2009 May 5. Review.


The role of metastasis suppressor genes in metastatic dormancy.

Horak CE, Lee JH, Marshall JC, Shreeve SM, Steeg PS.

APMIS. 2008 Jul-Aug;116(7-8):586-601. doi: 10.1111/j.1600-0463.2008.01213.x. Review.


Clinical-translational approaches to the Nm23-H1 metastasis suppressor.

Steeg PS, Horak CE, Miller KD.

Clin Cancer Res. 2008 Aug 15;14(16):5006-12. doi: 10.1158/1078-0432.CCR-08-0238. Review.


Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility.

Lee JH, Horak CE, Khanna C, Meng Z, Yu LR, Veenstra TD, Steeg PS.

Cancer Res. 2008 Feb 1;68(3):639-44. doi: 10.1158/0008-5472.CAN-07-2632.


Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2.

Horak CE, Mendoza A, Vega-Valle E, Albaugh M, Graff-Cherry C, McDermott WG, Hua E, Merino MJ, Steinberg SM, Khanna C, Steeg PS.

Cancer Res. 2007 Dec 15;67(24):11751-9.


Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth.

McDermott WG, Boissan M, Lacombe ML, Steeg PS, Horak CE.

Clin Exp Metastasis. 2008;25(2):131-8. Epub 2007 Dec 5.


Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.

Horak CE, Lee JH, Elkahloun AG, Boissan M, Dumont S, Maga TK, Arnaud-Dabernat S, Palmieri D, Stetler-Stevenson WG, Lacombe ML, Meltzer PS, Steeg PS.

Cancer Res. 2007 Aug 1;67(15):7238-46.


Translational approaches using metastasis suppressor genes.

Palmieri D, Horak CE, Lee JH, Halverson DO, Steeg PS.

J Bioenerg Biomembr. 2006 Aug;38(3-4):151-61. Review.


Metastasis gets site specific.

Horak CE, Steeg PS.

Cancer Cell. 2005 Aug;8(2):93-5.


Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer.

Palmieri D, Halverson DO, Ouatas T, Horak CE, Salerno M, Johnson J, Figg WD, Hollingshead M, Hursting S, Berrigan D, Steinberg SM, Merino MJ, Steeg PS.

J Natl Cancer Inst. 2005 May 4;97(9):632-42.


ExpressYourself: A modular platform for processing and visualizing microarray data.

Luscombe NM, Royce TE, Bertone P, Echols N, Horak CE, Chang JT, Snyder M, Gerstein M.

Nucleic Acids Res. 2003 Jul 1;31(13):3477-82.


Complex transcriptional circuitry at the G1/S transition in Saccharomyces cerevisiae.

Horak CE, Luscombe NM, Qian J, Bertone P, Piccirrillo S, Gerstein M, Snyder M.

Genes Dev. 2002 Dec 1;16(23):3017-33.


Global analysis of gene expression in yeast.

Horak CE, Snyder M.

Funct Integr Genomics. 2002 Sep;2(4-5):171-80. Epub 2002 Jul 10. Review.


ChIP-chip: a genomic approach for identifying transcription factor binding sites.

Horak CE, Snyder M.

Methods Enzymol. 2002;350:469-83. No abstract available.


GATA-1 binding sites mapped in the beta-globin locus by using mammalian chIp-chip analysis.

Horak CE, Mahajan MC, Luscombe NM, Gerstein M, Weissman SM, Snyder M.

Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2924-9. Epub 2002 Feb 26.


Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF.

Iyer VR, Horak CE, Scafe CS, Botstein D, Snyder M, Brown PO.

Nature. 2001 Jan 25;409(6819):533-8.


House-fly cytochrome P450 CYP6D1: 5' flanking sequences and comparison of alleles.

Scott JG, Liu N, Wen Z, Smith FF, Kasai S, Horak CE.

Gene. 1999 Jan 21;226(2):347-53.


Supplemental Content

Loading ...
Support Center